A Clinical Research About Ezetimibe On Improving Lipid Metabolism And Carotid Artery Atherosclerosis On Patients With Coronary Heart Disease

Objective:In this research,Clinical data of confirmed coronary heart disease(CHD)patients was randomly divided into combined treatment group and control group.Both the groups received standard“secondary prevention of CHD”.To explore the value of ezetimibe on CHD patients?treatment by contrasting blood lipid level,hypersensitive c-reactive protein(hs-CRP)level,carotid artery atherosclerosis Crouse index and major adverse cardiac events(MACE)rate in two groups before and after 1 year?s treatment.Methods:Using the method of random number table,clinical cases of 96 CHD patients,including 68 males and 28 females,hospitalized in our cardiovascular medicine department in the First Affiliated Hospital of Third Military Medical University from September 2013 to September 2014 were randomly selected into two groups on average according to the lipid lowing treatment plan.Thereinto,the lipid-lowing therapy program in combined treatment group was ezetimibe 10 mg daily plus rosuvastatin 10 mg nightly and in control group was only rosuvastatin 10 mg nightly.Patients complicated with hypertension and/or diabetes need accept the continued practice of drug control and the guiding measures of life habits at the sane time.Give a test of the total cholesterol(TC),triglyceride(TG),high density lipoprotein-cholesterol(HDL-C)and low density lipoprotein-cholesterol(LDL-C)at the beginning,after 6 months and 1 year?s treatment.Check the hs-CRP level,test the carotid artery intima media thickness(c IMT)and evaluate the carotid atherosclerotic plaque integrator by carotid ultrasound before and after 1 year?s treatment.We make a accurately record of the MACE rate,containing stable angina pectoris(SAP),unstable angina pectoris(UA)and acute myocardial infarction(AMI)in 1 year?s follow-up.Results:(1)Before the treatment,there was no obvious difference in the baseline data between combined treatment group and control group(p>0.05).(2)There was no obvious difference about the serum lipoprotein cholesterol levels of TC,TG,LDL-C,HDL-C,hs-CRP,cIMT and the carotid atherosclerotic plaque crouse integrator between the two groups before the treatment(p>0.05).(3)After 1 year?s treatment,the lipid level of TC,TG,LDL-C and hs-CRP in two groups was significantly lower than before.Comparing with control group,the date of TC,LDL-C and hs-CRP in combined treatment group declined more obviously.(4)The carotid atherosclerotic plaque integrator in combined treatment group was obviously lower than before and control group(p<0.05).The carotid atherosclerotic plaque integrator in control group has not obviously changed before and after treatment(p>0.05).(5)The MACE rate in combined treatment group was 6.3%,which was significantly lower than control group(p<0.05).Conclusion:(1)Patients with CHD accepted ezetimibe plus rosuvastatin?s treatment can better improve the TC,LDL-C level of lipid and the hs-CRP of inflammation factor.(2)Patients with CHD accepted ezetimibe plus rosuvastatin?s treatment can slow even recover the progress of carotid atherosclerosis and reduce the MACE rate.